172 related articles for article (PubMed ID: 36001255)
1. A New Combination: Anti Glypican-3 scFv and Diphtheria Toxin with the Best Flexible Linker.
Hashemi Yeganeh H; Heiat M; Alavian SM; Rezaei E
Protein J; 2022 Oct; 41(4-5):527-542. PubMed ID: 36001255
[TBL] [Abstract][Full Text] [Related]
2. DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study.
Hashemi Yeganeh H; Heiat M; Kieliszek M; Alavian SM; Rezaie E
Toxins (Basel); 2021 Oct; 13(11):. PubMed ID: 34822533
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
Fleming BD; Ho M
Toxins (Basel); 2016 Sep; 8(10):. PubMed ID: 27669301
[TBL] [Abstract][Full Text] [Related]
4. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
5. Optimization of the anti-(human CD3) immunotoxin DT389-scFv(UCHT1) N-terminal sequence to yield a homogeneous protein.
Hexham JM; King V; Dudas D; Graff P; Mahnke M; Wang YK; Goetschy JF; Plattner D; Zurini M; Bitsch F; Lake P; Digan ME
Biotechnol Appl Biochem; 2001 Dec; 34(3):183-7. PubMed ID: 11730486
[TBL] [Abstract][Full Text] [Related]
6. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv.
Wang Z; Kim GB; Woo JH; Liu YY; Mathias A; Stavrou S; Neville DM
Bioconjug Chem; 2007; 18(3):947-55. PubMed ID: 17352456
[TBL] [Abstract][Full Text] [Related]
7. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin.
Kim GB; Wang Z; Liu YY; Stavrou S; Mathias A; Goodwin KJ; Thomas JM; Neville DM
Protein Eng Des Sel; 2007 Sep; 20(9):425-32. PubMed ID: 17693455
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
Gao W; Tang Z; Zhang YF; Feng M; Qian M; Dimitrov DS; Ho M
Nat Commun; 2015 Mar; 6():6536. PubMed ID: 25758784
[TBL] [Abstract][Full Text] [Related]
9. Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH.
Liu X; Tan Q; Wen J; Wang X; Yang G; Li Y; Lu M; Ye W; Si A; Ma S; Ding T; Sun L; Liu F; Zhang M; Jiang T; Gao W
J Transl Med; 2023 Aug; 21(1):572. PubMed ID: 37626430
[TBL] [Abstract][Full Text] [Related]
10. Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma.
Wu T; Song Z; Huang H; Jakos T; Jiang H; Xie Y; Zhu J
Int Immunopharmacol; 2022 Dec; 113(Pt B):109393. PubMed ID: 36375323
[TBL] [Abstract][Full Text] [Related]
11. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
[TBL] [Abstract][Full Text] [Related]
13. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update.
Fleming BD; Ho M
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32575752
[TBL] [Abstract][Full Text] [Related]
14. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Mohseni Z; Sedighian H; Halabian R; Amani J; Behzadi E; Imani Fooladi AA
Eur J Pharmacol; 2021 May; 899():174057. PubMed ID: 33753109
[TBL] [Abstract][Full Text] [Related]
15. [Construction and expression of the fusion protein DT389-hIL-13 and its cytotoxicity to glioma cell lines].
Tuo HZ; Wang JW; Wang DX; Li JM; Ouyang J; Hong T
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):1024-8. PubMed ID: 15312540
[TBL] [Abstract][Full Text] [Related]
16. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.
Wang C; Gao W; Feng M; Pastan I; Ho M
Oncotarget; 2017 May; 8(20):32450-32460. PubMed ID: 27419635
[TBL] [Abstract][Full Text] [Related]
17. Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma.
Li J; Xiang L; Wang Q; Ma X; Chen X; Zhu Y; Yang Y; Huang L; He H; Xu L; Liang X; Dong S; Hu S; Li H; Feng M
J Cancer; 2022; 13(4):1370-1384. PubMed ID: 35281879
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.
Hanaoka H; Nagaya T; Sato K; Nakamura Y; Watanabe R; Harada T; Gao W; Feng M; Phung Y; Kim I; Paik CH; Choyke PL; Ho M; Kobayashi H
Mol Pharm; 2015 Jun; 12(6):2151-7. PubMed ID: 25955255
[TBL] [Abstract][Full Text] [Related]
19. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y; Gao W; Man YG; Nagata S; Ho M
MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
